Prostaglandins, thromboxanes and leukotrienes, their derivatives and structural analogues

In 2024, prostaglandins, thromboxanes and leukotrienes, their derivatives and structural analogues trade exhibited modest growth, with global flows reaching $310,720,845 and a three-year compound annual growth rate of -6.4% (five-year: -0.8%). The all-time peak of $1,568,397,193 was recorded in 2007; the current level is 80% below that high-water mark.

Over the 30-year observation window (1995–2024), 62% of years recorded positive growth, indicating a mildly upward trajectory with periodic contractions. Trend momentum is steady (-0.4% acceleration).

The supply side is diversified (Herfindahl-Hirschman Index 0.126). The three largest exporters — Czechia ($63.7M), Hungary ($51.4M), and United States ($45.3M) — collectively dominate supply flows. The leading exporter has grown at -14.8% over the last three years.

On the demand side, importer concentration is diversified (HHI 0.075). The three largest import markets are Germany ($44.8M), Japan ($39.0M), and France ($29.1M). The largest importing market sources from 26 different supplying countries.

The dominant trade corridor is Czechia → Germany at $37.7M, representing 84.0% of the importer's total demand.

The volatility score for prostaglandins, thromboxanes and leukotrienes, their derivatives and structural analogues is 3 out of 100, classified as low. Trade flows are relatively stable compared to other HS6 products, suggesting mature supply chains and predictable demand.

For market entrants, modest but steady demand provides a reasonable entry window. The diversified supply landscape means many competitors but also multiple entry points and buyer relationships to target.

Data confidence is rated "High" based on reporting coverage and consistency across OECD member and partner countries.